Kane Biotech (TSE:KNE) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kane Biotech has seen a substantial revenue increase in the third quarter of 2024, primarily driven by the first commercial sale of its revyve™ Antimicrobial Wound Gel. The company also announced significant corporate developments, including new distribution agreements and regulatory approvals, positioning it well for future growth in the wound care market.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.